Trial · NCT02390362
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
NCT02390362, Phase 3, Terminated, Nationwide Children's Hospital; results first posted 2019-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome. Trials, record NCT02390362. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02390362
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
- NCT number
- NCT02390362
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 3 participants, actual
- Lead sponsor
- Nationwide Children's Hospital
- Conditions
- Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
- Interventions
- Rituximab, MMF
- First posted
- 2015-03-17
- Last updated
- 2019-03-26
- Results first posted
- 2019-03-26
- Limitations and caveats
Study terminated early, sponsor pulled funding associated with enrollment milestones. At the time of termination, 2 subjects were active in the study. 1 was randomized to study drug, the other to the comparator drug. Not enough data for analysis.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Relapse Free Survival | 6 months | |
| Secondary | Relapse Free at 12 Months | 12 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Relapse Free Survival | 6 months | Study terminated early. Only three subjects were enrolled and results will not be posted to protect subject confidentiality. | ||
| SECONDARY | Relapse Free at 12 Months | 12 months | Study terminated early. Only 3 subjects enrolled. Data will not be posted to protect the subject identity. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rituximab | 1 | |
| Overall Study | STARTED | Mycophenolate Mofetil (MMF) | 2 | |
| Overall Study | COMPLETED | Rituximab | 1 | |
| Overall Study | COMPLETED | Mycophenolate Mofetil (MMF) | 1 | |
| Overall Study | NOT COMPLETED | Rituximab | 0 | |
| Overall Study | NOT COMPLETED | Mycophenolate Mofetil (MMF) | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rituximab | 0 | 1 |
| Total, all-cause mortality | Mycophenolate Mofetil (MMF) | 0 | 2 |
| Total, other adverse events | Rituximab | 0 | 1 |
| Total, other adverse events | Mycophenolate Mofetil (MMF) | 0 | 2 |
| Total, serious adverse events | Rituximab | 0 | 1 |
| Total, serious adverse events | Mycophenolate Mofetil (MMF) | 0 | 2 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39513526 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Rituximab vs Mycophenolate Mofetil (MMF): deaths from any cause | Trial comparisons |
| Rituximab vs Mycophenolate Mofetil (MMF): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02390362
GET https://conductscience.org/api/trials/v1/NCT02390362/registered